uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Beats Expectations By $0.25 EPS

uniQure (NASDAQ:QURE) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25, Zacks reports. The company had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%.

uniQure Trading Up 4.3 %

QURE opened at $12.78 on Friday. The business has a 50 day moving average of $12.22 and a 200-day moving average of $12.09. The stock has a market cap of $700.04 million, a PE ratio of -2.58 and a beta of 0.10. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Activity at uniQure

In related news, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the sale, the chief financial officer now directly owns 152,372 shares in the company, valued at $1,630,380.40. This trade represents a 8.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew C. Kapusta sold 28,341 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at $6,703,461.66. This represents a 4.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock valued at $961,401 over the last ninety days. Insiders own 4.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on QURE shares. Wells Fargo & Company cut their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $38.00 price objective on shares of uniQure in a research report on Tuesday, May 6th. StockNews.com raised shares of uniQure to a “sell” rating in a report on Tuesday, March 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of uniQure in a report on Monday, April 21st. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $38.80.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.